|
LINE1 CpG site
|
# events/# patients*
|
Extent methylation†
|
Median OS (95%CI)‡
|
5 year OS (%)
|
|---|
|
CpG1
|
13/21
|
<25.68
|
24.3 (11.1-inf)
|
39
|
| |
17/21
|
≥25.68
|
15.3 (6.8-26.9)
|
16
|
|
CpG2
|
12/21
|
<27.26
|
31.5 (12.5-inf)
|
43
|
| |
18/21
|
≥27.26
|
11.5 (6.8-20.9)
|
13
|
|
CpG3
|
11/21
|
<40.46
|
31.9 (13.1-inf)
|
48
|
| |
19/21
|
≥40.46
|
11.5 (9.2-20.6)
|
7
|
- * number of patients who died (# events) and total number of patients in the group (# patients) are reported;
- † Patients were divided according to the % of methylation of the specified CpG site being < or ≥ the median % methylation measured in the examined patients' population;
- ‡ Survival functions were calculated by the Kaplan-Meier method. Data are reported as Median OS in months, together with the corresponding 95% Confidence Intervals (CI).
